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A 35-year-old woman with an acute-on-chronic lithium overdose received multiple oral
doses of sodium polystyrene sulfonate totaling 120 g over a 24-h period. During the 72 h
after the institution of therapy, the serum lithium level decreased from 3.80 to 0.42 mEq/L.
Multiple doses of sodium polystyrene sulfonate may be useful in lowering the serum
lithium level in severely ill patients with acute renal failure, and can substitute
hemodialysis.1. Introduction
Lithium salts are prescribed routinely for prophylactic control
of manic-depressive episodes (bipolar affective disorders) and a
treatment of acute mania. Lithium pharmacokinetics is subject to
considerable interindividual differences that, given a narrow
therapeutic window, dictate close monitoring of serum
concentrations[1].
Therapeutic concentrations are 0.6–1.2 mmol/L for prophy-
lactic control of mania and 1.0–1.5 mmol/L for treatment of
acute mania. Symptoms of toxicity may present at 1.5 mmol/L,
but it can vary with the individual and the time course of
exposure[2,3].
Lithium toxicity can cause death and severe morbidity, and
may have renal, gastrointestinal, endocrine and predominantly
neurologic manifestations[3–5]. Therefore, management of lithium
intoxication includes ﬂuid resuscitation, electrolyte and acid/
base management, and methods to decrease absorption and
increase lithium elimination[6].
Here, we reported a case in which sodium polystyrene sul-
fonate (SPS) was used in the treatment of a patient with a severe
acute-on-chronic lithium poisoning.2. Case presentation
The medications of a 35-year-old woman with a history of
manic depression included a twice-daily regimen of 500 mg
lithium. She was referred to the emergency room because of
agitation, confusion and hypovolemic shock due to a
diarrhea.
The patient's vital signs were as follows on arrival: blood
pressure 77/60 mmHg, pulse rate 160 beats/min and regular,
respiratory rate 30 breaths/min, rectal temperature 38.4 C, room
air oxygen saturation 99%, ﬁnger stick glucose level 132 mg/dL
and her level of consciousness was 10 (eyes 4; voice 2; motor 4)
on the Glasgow coma score.
The laboratory data revealed hemoglobin of 10.6 g/dL, he-
matocrit of 21%, platelet count of 223000, sodium of 133 mEq/L,
potassium of 3.4 mEq/L, chloride of 105 mEq/L, glucose of
120 mg/dL, blood urea nitrogen of 306.3 mg/dL, creatinine of
4.52 mg/dL and serum lithium of 3.82 mEq/L. In addition, her
liver function was normal.
An arterial blood gas analysis showed perturbed ﬁndings as
follows: pH, 7.66; arterial partial pressure of carbon dioxide,
27 mmHg; arterial partial pressure of oxygen, 87.8 mmHg; base
excess, 8.1 mmol/L.
Her electrocardiogram was normal. Besides, a CT scan of the
brain was performed and showed a chronic hydrocephaly
(Figure 1).access article under the CC BY-NC-ND license
Figure 1. CT scan showing ﬁndings of chronic compensated hydroceph-
alus leading to normal pressure hydrocephalus.
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Figure 3. Serum urea concentration evolution.
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Figure 4. Serum creatinine concentration evolution.
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ventilation, ﬂuid resuscitation and norepinephrine infusion.
Empirically, intravenous ciproﬂoxacin and amoxicillin/clav-
ulanic acid were initiated. The complementary tests performed to
ﬁnd the focus of infection (urine culture, tracheal aspirate) were
negative.
An oral administration of 30 g SPS every 6 h was prescribed,
for a total of nine doses and the patient received 3000 mL of 5%
dextrose in water with 0.45% saline solution (300 mEq sodium)
and 52 mEq of supplemental potassium intravenous perfusion
during the ﬁrst 48 h of her hospital stay.
The mean values of repeat serum sodium and potassium
levels at the end of SPS therapy were 140.00 mEq/L and
3.63 mEq/L, respectively.
Serial serum lithium determinations were carried out and the
level was noted to return to the therapeutic range at 72 h after
SPS administration (Figure 2) and the renal function returned to
the normal (Figures 3 and 4). Unfortunately, the patient was
complicated by multiple organ failure syndrome and died eleven
days after disease onset.6.0
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Figure 2. Serum lithium levels during SPS administration.3. Discussion
Lithium carbonate has been used as an invaluable drug in the
treatment of manic-depressive illness. Its main disadvantage is a
narrow therapeutic window: therapeutic concentrations of 0.6–
1.2 mmol/L for prophylactic control of mania and 1.0–
1.5 mmol/L for treatment of acute mania. In fact, lithium toxicity
can cause death and severe morbidity, and may have renal,
gastrointestinal, endocrine and predominantly neurologic mani-
festations[4,5,7]. It is known that lithium competes with sodium
and potassium at the renal tubular level, therefore, sodium and
water balance cause not only the serum level of lithium but
also its toxicity. The most important in lithium toxicity is
dehydration, which will produce sodium and water
imbalance[6,7]. Concerning lithium toxicity management, the
hemodialysis is indicated if the lithium concentration in serum
is: (a) > 4.0 mmol/L, regardless of patients' presentation; (b)
> 2.5 mmol/L in markedly symptomatic patients within
36 h[7,8]. Theoretically, hemodialysis is the most effective when
it is instituted early, before equilibration with extravascular
and intracellular compartments and thereby the lithium
removing is more rapidly. Early extensive hemodialysis may
also reduce toxicity by minimizing tissue concentrations and
by limiting the postdialysis rebound inherent with re-
equilibration[8–10].
Our patient was presented with a severe degree of intoxica-
tion, based on the amount of drug ingested, the initial serum
lithium level, the impairment of renal function, the severity of
neurologic symptoms, and systemic manifestations. She devel-
oped acute renal failure probably as result of volume depletion
since it was rapidly reversible by infusion therapy and SPS
administration without the necessity of hemodialysis.
As evident from our case, saline diuresis was found to be an
ineffective method for lithium elimination[11]. An effective oral
Chakroun-Walha Olfa et al./Journal of Acute Disease 2016; 5(2): 162–164164treatment adjunct is the administration of sodium polystyrene
sulfate, which can prevent lithium absorption when it is used
early after ingestion[12,13]. In fact, SPS has been shown in an
animal model to increase lithium elimination even when
lithium was given parenterally and recently[14]. A retrospective
cohort study suggested that SPS was capable of promoting
lithium elimination in chronic intoxications[15].
We suggest that SPS may be useful in treating a subset of
clinically sever patients with a toxic serum lithium level. It can
be also considered as an alternative to hemodialysis in seriously
lithium-intoxicated individuals. Further evaluation of SPS in a
randomized, blinded clinical trial(s) will be required.
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